Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shenqi Pill and Xihuang Pill intervention study in prostate cancer
ChiCTR2200065971Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Hunan University of Chinese Medicine
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Bawei Shenqi Pill, Xihuang Capsule and abiraterone in prostate cancer (PCa) and castration-resistant prostate cancer (CRPC) (6 arms), sponsored by First Affiliated Hospital of Hunan University of Chinese Medicine. Primary endpoints: Overall survival, Progression-free survival and 1 more. Started Jan 2021; status: recruiting.
02
Drugs
Bawei Shenqi PillXihuang Capsuleabiraterone
03
Conditions
prostate cancer (PCa)castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on ChiCTR2200065971.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200065971.